According to incomplete statistics from Innovation Radar, from July 21 to July 27, the global biopharmaceutical fieldA Total of 16 Transaction Events Disclosed, with a Potential Transaction Value Exceeding $5.65 BillionThe transaction involves multiple fields, including monoclonal antibodies, gene editing, CAR-T cell therapy, vaccines, nuclear medicine, and covalent agents.

Among them,Novatim and U.S.-based ERIGEN Reach Exclusive Overseas Licensing Agreement for Dual-Targeting CAR-T Therapy KQ-2003, becoming one of the most eye-catching deals last week.Novatim will receive a total amount of $2.135 billion, including a recent development milestone payment of $15 million.KQ-2003 targets BCMA and CD19 for the treatment of relapsed/refractory multiple myeloma (rrMM) and POEMS syndrome, and has now entered Phase 1b clinical trials in China. The therapy, through a parallel structural design and optimized signaling domain, aims to enhance the persistence and anti-tumor activity of CAR-T cells, potentially reducing the risk of recurrence.

Last week, large multinational pharmaceutical companies (MNCs) such as Eli Lilly, Novartis, and Sanofi were involved in several high-value cooperation and acquisition deals.

In the field of infectious diseases,Sanofi Acquires ViceBio for $1.6 Billion, further expanding the respiratory vaccine pipeline, particularly for the development of combination vaccines targeting Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV). This acquisition not only brings early-stage bivalent vaccine candidates VXB-241 and VXB-251 but also introduces Vicebio's Molecular Clamp technology, enhancing vaccine design and development.

In addition to the acquisition of ViceBio,Sanofi also reached a cooperation with Novatim.Based on the Kling-Select platform, monoclonal antibodies with potent neutralizing activity for epitope identification were discovered, aiming to develop next-generation antiviral therapies targeting clinically relevant human viral pathogens.

In the field of autoimmune diseases,Matchpoint Therapeutics Reaches Up to $1.06 Billion Collaboration Agreement with Novartis, Including $60 Million Upfront PaymentThe two parties will utilize Matchpoint Therapeutics' Affinity Covalent Exploration (ACE) platform to develop oral covalent agents for the treatment of various inflammation-related diseases. This technology aims to leverage the properties of covalent chemistry to target difficult-to-drug protein targets, precisely inhibiting their function, thereby reducing the production of pro-inflammatory cytokines and chemokines. This transaction also marks Novartis' continued investment in exploring new therapies for inflammatory and autoimmune diseases.

In recent years, Eli Lilly has continued to invest heavily in innovative therapies and actively laid out cutting-edge technologies that can break through traditional treatment bottlenecks. In the latest collaboration,Lilly Announces Collaboration with Gate Bioscience to Develop "Molecular Gates" Novel Therapy, Potential Total Deal Value Reaches $856 MillionThe core mechanism of the "molecular gate" is to inhibit the occurrence of diseases at the source by selectively blocking the pathway through which pathogenic proteins are transported from the endoplasmic reticulum. Gate Bioscience stated that these small-molecule drugs can be administered orally and are able to cross the blood-brain barrier, making them suitable for treating a variety of diseases with high unmet needs, including neurological disorders.

Readers, please star⭐Chuangjianhui to receive updates第一时间.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views mentioned. This article does not constitute a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share with your friends circle individually. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Innovation Insights"Contact us through the WeChat Official Account comments.

More Data Content Recommended

Click "InSee", Sharing Innovation and Health News from Jianjianhui